The update is qualitative and lacks hard financial data or concrete near-term catalysts. Traders should monitor for completion of the expanded ADAPT cohort enrollment, next-stage Ultrasome study design, and any partnership announcements. The absence of financial guidance or capital raise details limits immediate trading implications.
Price Chart
Executive Summary
Creative Medical Technology Holdings issued a mid-year CEO update highlighting clinical progress across its Olastrocel (CELZ-201) chronic lower back pain program, Ultrasome osteoarthritis platform, and CELZ-Biodefense Toxic Exposure Atlas. The update reports positive interim ADAPT trial data, FDA clearance for an expanded cohort, and breakthrough pilot results for Ultrasome, but provides no financial figures, guidance, or material near-term catalysts. The release is forward-looking and promotional in tone, lacking quantitative data to support a directional trading signal.
Key Facts
- WHO approved 'Olastrocel' as International Non-Proprietary Name for CELZ-201 in late 2025.
- Positive interim blinded 180-day data from ADAPT trial showed statistically significant improvements in disability and pain with no serious adverse events.
- FDA cleared expansion of ADAPT trial to enroll an additional cohort of patients receiving <90 mg/day morphine equivalents; cohort is >85% enrolled.
- Ultrasome pilot study achieved primary endpoint with 93% of patients showing clinically meaningful improvements in mobility and pain reduction.
- BioDefense Inc. Burn Pit Initiative received regulatory approval to proceed nationally; Project PHOENIX advanced to nationwide AI-enabled virtual data collection targeting 1,000 veterans.
- Company states it is not compelled to pursue dilutive financings and will prioritize non-dilutive funding sources.
Financial Impact
No financial figures provided in the press release; company is pre-revenue clinical-stage biotech with $5M market cap.
Risk Factors
- Clinical-stage biotech with no approved products or revenue; high reliance on successful trial outcomes and regulatory approvals.
- Small market cap ($5M) and low liquidity may amplify price swings on any news.
- Forward-looking statements subject to risks including patient enrollment, regulatory feedback, and competition.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3320639 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | SC 13D | $0.9464 $0.9200 | ▼ −2.79% | ▼ −3.46% | $0.7120 (−24.77%) |
Sep 25, 2026 4w ago | 8-K | $1.01 $0.9652 | ▼ −4.44% | ▼ −4.25% | $0.7120 (−29.50%) |
Sep 17, 2026 5w ago | Press Release | $0.8775 $0.9659 | ▲ +10.07% | ▲ +10.19% | $0.7120 (−18.86%) |
Aug 20, 2026 9w ago | Press Release | $1.28 $1.31 | ▲ +2.34% | ▲ +1.93% | $0.7120 (−44.37%) |
Jul 1, 2026 16w ago | Press Release | $1.27 $1.21 | ▼ −4.72% | ▼ −4.59% | $0.7120 (−43.94%) |
Jun 30, 2026 16w ago | Press Release | $1.45 $1.27 | ▲ +12.41% | ▲ +12.28% | $0.7120 (+50.90%) |
Jun 26, 2026 17w ago | S-1/A | $0.8102 $1.45 | ▼ −78.97% | ▼ −78.19% | $0.7120 (+12.12%) |
Jun 25, 2026 17w ago | S-1 | $1.20 $0.8102 | ▼ −32.48% | ▼ −34.13% | $0.7120 (−40.67%) |
Jun 22, 2026 18w ago | Press Release | $1.93 $1.97 | ▲ +2.07% | ▲ +3.52% | $0.7120 (−63.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers